<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893798</url>
  </required_header>
  <id_info>
    <org_study_id>A6791042</org_study_id>
    <secondary_id>2021-001035-54</secondary_id>
    <nct_id>NCT04893798</nct_id>
  </id_info>
  <brief_title>A Study Comparing Subcutaneous Injection of Sayana Press In the Upper Arm Versus Anterior Thigh and Abdomen</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO COMPARE THE PHARMACOKINETICS AND RELATIVE BIOAVAILABILITY OF MEDROXYPROGESTERONE ACETATE IN HEALTHY FEMALE PARTICIPANTS FOLLOWING SUBCUTANEOUS INJECTION OF SAYANA PRESS IN THE UPPER ARM RELATIVE TO ANTERIOR THIGH AND ABDOMEN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the pharmacokinetics and relative bioavailability of&#xD;
      medroxyprogesterone in healthy female participants following subcutaneous injection of Sayana&#xD;
      Press into the upper arm versus anterior thigh and abdomen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">April 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Trough Concentration (Ctrough) of Medroxyprogesterone</measure>
    <time_frame>Day 92 post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve from time zero to end of dosing interval (AUCtau)</measure>
    <time_frame>pre-dose, up to 92 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of Medroxyprogesterone</measure>
    <time_frame>pre-dose, up to 92 days post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Progesterone Level</measure>
    <time_frame>pre-dose, up to 99 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Estradiol Level</measure>
    <time_frame>pre-dose, up tp 99 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Luteinizing Hormone (LH) Level</measure>
    <time_frame>pre-dose, up to 99 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Follicle-Stimulating Hormone (FSH) Level</measure>
    <time_frame>pre-dose, up to 99 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Informed consent document to 150 days post dose or until study completion, whichever is longer.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs</measure>
    <time_frame>baseline, up to 150 days post dose or until study completion, whichever is longer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities</measure>
    <time_frame>Screening, Day 1, up to 150 days post dose or until study completion, whichever is longer</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sayana Press, Upper Arm injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sayana Press, administered subcutaneously into upper arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sayana Press, anterior thigh</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sayana Press, administered subcutaneously into anterior thigh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sayana Press, abdomen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sayana Press, administered subcutaneously into abdomen</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Sayana Press</intervention_name>
    <description>Sayana Press is a drug-device combination and is considered a medical product in the EU.</description>
    <arm_group_label>Sayana Press, Upper Arm injection</arm_group_label>
    <arm_group_label>Sayana Press, abdomen</arm_group_label>
    <arm_group_label>Sayana Press, anterior thigh</arm_group_label>
    <other_name>Medroxyprogesterone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pre-menopausal female participants, 18 to 45 years of age, inclusive, at the time of&#xD;
             signing the ICD who are at low risk of pregnancy&#xD;
&#xD;
          -  Participants who have a regular menstrual cycle (between 21 and 42 days in length).&#xD;
&#xD;
          -  No previous injection of depot MPA for 1 year prior to enrollment.&#xD;
&#xD;
          -  BMI of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of abnormal cervical cytology within the last 3 years that has not been&#xD;
             adequately treated (at least 2 subsequent normal smears). However, ASCUS is permitted&#xD;
             in this study.&#xD;
&#xD;
          -  Known or suspected malignancy of the breast or genital organs.&#xD;
&#xD;
          -  Known with metabolic bone disease.&#xD;
&#xD;
          -  Undiagnosed abnormal genital bleeding.&#xD;
&#xD;
          -  Known or suspected pregnancy; or nursing females.&#xD;
&#xD;
          -  History of febrile illness within 5 days prior to the first dose.&#xD;
&#xD;
          -  Participant with active thrombophlebitis or whose medical history suggests that they&#xD;
             may be at increased risk for osteoporosis, thromboembolic disease or cerebral vascular&#xD;
             disease.&#xD;
&#xD;
          -  Use of prescription or nonprescription drugs, vitamins, herbal preparations and&#xD;
             dietary supplements capable of inducing hepatic metabolism (eg, barbiturates,&#xD;
             rifampicin, carbamazepine or St John's Wort) or any medication known to be a&#xD;
&#xD;
          -  cytochrome P450 inhibitor within 30 days (or 5 half-lives of the substance, whichever&#xD;
             is longer) of enrollment in the study&#xD;
&#xD;
          -  Use of hormonal contraception (including hormone releasing intrauterine device) within&#xD;
             the last 3 months (and should have resumed regular menstruation).&#xD;
&#xD;
          -  Baseline 12-lead ECG that demonstrates clinically relevant abnormalities that may&#xD;
             affect participant safety or interpretation of study results (eg, baseline QTc&#xD;
             interval &gt;450 msec, complete LBBB, signs of an acute or indeterminate-age myocardial&#xD;
             infarction, ST-T interval changes suggestive of myocardial ischemia, second- or&#xD;
             third-degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the&#xD;
             baseline uncorrected QT interval is &gt;450 msec, this interval should be rate-corrected&#xD;
             using the Fridericia method and the resulting QTcF should be used for decision&#xD;
&#xD;
          -  making and reporting. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should&#xD;
             be repeated 2 more times and the average of the 3 QTc or QRS values should be used to&#xD;
             determine the participant's eligibility. Computer-interpreted ECGs should be overread&#xD;
             by a physician experienced in reading ECGs before excluding participants.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brussels Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-capitale, RÃ©gion DE</state>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A6791042</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

